Nanoviricides (NNVC) Amortization of Deferred Charges (2014 - 2017)
Nanoviricides (NNVC) posted Amortization of Deferred Charges of $119863.0 for Q4 2017, down 49.92% sequentially from $239351.0 in Q3 2017, and down 71.68% YoY from $423287.0 in Q4 2016.
Nanoviricides (NNVC) Amortization of Deferred Charges (2014 - 2017) Analysis & Trends
Nanoviricides has reported Amortization of Deferred Charges for 4 years, with the latest figure at $119863.0 in Q4 2017.
- Quarterly Amortization of Deferred Charges fell 71.68% year-over-year to $119863.0 in Q4 2017, while the trailing twelve-month figure through Sep 2018 was $119863.0 (down 89.87% YoY) and the FY2018 annual result came in at $359214.0, down 73.35% from the prior year.
- Amortization of Deferred Charges fell to $119863.0 in Q4 2017 per NNVC's latest filing, from $239351.0 in the prior quarter.
- Over five years, Amortization of Deferred Charges peaked at $569495.0 in Q2 2014 and troughed at $119863.0 in Q4 2017.
- A 4-year average of $325267.9 and a median of $314890.0 in 2015 frame the typical range for Amortization of Deferred Charges.
- The sharpest annual moves came in 2015 and 2017: Amortization of Deferred Charges rose 22.14% in 2015, then slumped 71.68% in 2017.
- Over 4 years, Amortization of Deferred Charges stood at $289960.0 in 2014, then increased by 20.69% to $349960.0 in 2015, then gained by 20.95% to $423287.0 in 2016, then plunged by 71.68% to $119863.0 in 2017.
- According to Business Quant data, Amortization of Deferred Charges over the past three periods registered $119863.0, $239351.0, and $223337.0 for Q4 2017, Q3 2017, and Q2 2017 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Nanoviricides | 28.74 Mn | 25.53 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | 119,863.00 |
| Dec 31, 2017 | 119,863.00 |
| Sep 30, 2017 | 239,351.00 |
| Sep 30, 2017 | 239,351.00 |
| Jun 30, 2017 | 223,337.00 |
| Jun 30, 2017 | 223,337.00 |
| Mar 31, 2017 | 297,662.00 |
| Mar 31, 2017 | 297,662.00 |
| Dec 31, 2016 | 423,287.00 |
| Dec 31, 2016 | 423,287.00 |
| Sep 30, 2016 | 403,462.00 |
| Sep 30, 2016 | 403,462.00 |
| Jun 30, 2016 | 380,555.00 |
| Jun 30, 2016 | 380,555.00 |
| Mar 31, 2016 | 362,993.00 |
| Mar 31, 2016 | 362,993.00 |
| Dec 31, 2015 | 349,960.00 |
| Dec 31, 2015 | 349,960.00 |
| Sep 30, 2015 | 333,710.00 |
| Sep 30, 2015 | 333,710.00 |